| Features: |
| Erastin is often referred to as a "metabolic inhibitor" or a "ferroptosis inducer", rather than a traditional chemotherapy agent. Erastin is primarily available as a research chemical—it's not an approved therapeutic for clinical use. Pathways: -Erastin inhibits system xCT, thereby reducing cystine uptake. This leads to decreased intracellular cysteine, a precursor for GSH. As a consequence, the cell’s glutathione levels drop, compromising its ability to neutralize reactive oxygen species (ROS). -Glutathione (GSH) Depletion and Increased Oxidative Stress -Voltage-Dependent Anion Channels (VDACs): Altering VDAC function can affect mitochondrial metabolism, leading to changes in energy production and further enhancing oxidative stress. |
| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -caffeic acid phenethyl ester -flavopiridol -oleandrin -ursolic acid -butein -betulinic acid |
| 727- | Bor, | RSL3, | erastin, | Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy |
| - | in-vitro, | Liver, | HepG2 |
| 5047- | erastin, | The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells |
| - | in-vitro, | Ovarian, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:241 Target#:1106 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid